Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 238 Parkinson's trials, 4 stopped | 0.94 |
| literature PubMed | 63 Parkinson's papers of 14,967 | 0.45 |
| pathways Reactome | 6 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 9015
Sealed predictions
- BID in dopamine neurons, braak-0.60 (p 0.089) → -0.16 (p 0.682)receipt 9023
Swarm cases
receipt 9023: BID in dopamine neurons, braak
- power
- full sample -0.29 (p 0.235, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.39 (p 0.114, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.109, n 18). could be the mix.
- skeptic
- leave-one-out range -0.49 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.235, n 18). fragile.
- cell type
- strongest in microglia: -0.61 (p 0.0072, n 18) vs -0.29 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BID in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up BID · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.20 p 0.477 (needs p < 2.4e-4)
Receipts
loading the receipts